What if a medication that does not directly lower cholesterol could still reduce your risk of a heart attack or stroke? That is the question surrounding low-dose colchicine, an older prescription drug traditionally associated with gout and certain inflammatory conditions.
Colchicine is now receiving attention because research suggests it may calm inflammation inside artery walls, stabilize vulnerable plaque, and lower the risk of major cardiovascular events in carefully selected people. But headlines can easily stretch “reduces cardiovascular risk” into “clears your arteries,” and those are not the same claim.
Before you ask your doctor about colchicine, it helps to understand what the evidence actually shows, who may benefit, and why this is not a medication to experiment with on your own. (Based on the insights of Dr. Ford Brewer, MD, MPH)
Key takeaways
- Artery plaque is not simply cholesterol or grease collecting inside a pipe; inflammation plays an important role in making plaque unstable.
- Low-dose colchicine may reduce the risk of heart attacks and strokes in some people with established cardiovascular disease.
- The strongest evidence supports plaque stabilization and fewer cardiovascular events—not completely clean arteries.
- Colchicine has a narrow safety margin and can interact with common medications.
- Kidney and liver function, current medications, and overall cardiovascular risk must be reviewed before treatment.
- Medication cannot replace nutrition, physical activity, sleep, smoking cessation, or other foundations of heart health.
1. Colchicine is an anti-inflammatory medication, not a cholesterol drug
Colchicine has been used for decades to treat gout flares because it helps reduce the inflammatory response triggered by uric acid crystals. It does not work like a statin, which primarily lowers LDL cholesterol and also has some anti-inflammatory effects. It also does not act like an anticoagulant or antiplatelet drug that directly prevents blood from clotting.
Instead, colchicine appears to quiet specific inflammatory pathways. In